- Home
- MYSE vs HOTH Comparison
MYSE vs HOTH Comparison
Compare MYSE & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYSE | HOTH |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 12.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MYSE | HOTH |
|---|---|---|
| Price | $1.85 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 6.0M | 395.0K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.49 |
| 52 Week High | $5.77 | $2.12 |
Technical Indicators
Market Signals| Indicator | MYSE | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 38.59 |
| Support Level | $1.64 | $0.49 |
| Resistance Level | $2.07 | $0.80 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 13.24 | 11.82 |
Price Performance
Historical ComparisonAbout MYSE Myseum Inc.
Myseum.AI Inc is an integrate proprietary privacy-first artificial intelligence (AI) and social media technology company. The Company is developing privacy-first agentic localized AI agents to assist in managing personal media such as photos, videos and messages, while maintaining privacy.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.